NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $0.59 -0.04 (-6.35%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.56▼$0.6650-Day Range$0.59▼$1.0852-Week Range$0.56▼$3.25Volume260,561 shsAverage Volume341,368 shsMarket Capitalization$28.70 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cue Biopharma alerts: Email Address Cue Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside747.5% Upside$5.00 Price TargetShort InterestHealthy7.52% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.87) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.75 out of 5 starsMedical Sector205th out of 910 stocksPharmaceutical Preparations Industry86th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCue Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.52% of the outstanding shares of Cue Biopharma have been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Cue Biopharma has recently decreased by 9.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCue Biopharma has received a 74.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cue Biopharma is -0.58. Previous Next 2.0 News and Social Media Coverage News SentimentCue Biopharma has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cue Biopharma this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows6 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.49% of the stock of Cue Biopharma is held by insiders.Percentage Held by InstitutionsOnly 35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($0.87) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Cue Biopharma Stock (NASDAQ:CUE)Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More CUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CUE Stock News HeadlinesSeptember 3, 2024 | finance.yahoo.comCue Biopharma to Present at The Promise of Interleukin-2 Therapy ConferenceAugust 20, 2024 | ca.finance.yahoo.comQ2 2024 Cue Biopharma Inc Earnings CallSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 20, 2024 | markets.businessinsider.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 20, 2024 | msn.comCue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call TranscriptAugust 19, 2024 | globenewswire.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsJuly 26, 2024 | bizjournals.comCuts at Cue Biopharma include CEO salary, 25% of jobsJuly 26, 2024 | markets.businessinsider.comCue Biopharma Receives ‘Buy’ Rating Amid Strategic Shift and Promising Autoimmune Therapeutics PipelineSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankJuly 26, 2024 | finance.yahoo.comCue Biopharma downsizes to focus on autoimmune pipelineJuly 25, 2024 | uk.finance.yahoo.comApplied Intuition raises $300M four months after raising $250MJuly 25, 2024 | finance.yahoo.comCue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital RequirementsMay 30, 2024 | investorplace.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 16, 2024 | markets.businessinsider.comCue Biopharma’s Promising Future: A Comprehensive Buy Rating JustificationMay 11, 2024 | finance.yahoo.comCue Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)May 10, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsSee More Headlines Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CUE CUSIPN/A CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+747.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,730,000.00 Net Margins-566.02% Pretax Margin-566.02% Return on Equity-142.93% Return on Assets-82.85% Debt Debt-to-Equity Ratio0.11 Current Ratio2.06 Quick Ratio2.06 Sales & Book Value Annual Sales$8.30 million Price / Sales3.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book1.34Miscellaneous Outstanding Shares48,643,000Free Float45,000,000Market Cap$28.70 million OptionableOptionable Beta1.96 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Daniel R. Passeri J.D. (Age 63)M.Sc., CEO & Director Comp: $607.98kDr. Anish Suri Ph.D. (Age 50)President & Chief Scientific Officer Comp: $447.34kMs. Kerri-Ann Millar (Age 54)Chief Financial Officer Comp: $447.34kDr. Ronald D. Seidel III (Age 48)Ph.D., Co-Founder Comp: $316.63kMr. Colin G. Sandercock J.D. (Age 67)MSE, Senior VP, General Counsel & Secretary Comp: $381.42kDr. Matteo Levisetti M.D. (Age 55)Chief Medical Officer More ExecutivesKey CompetitorsKodiak SciencesNASDAQ:KODCadrenal TherapeuticsNASDAQ:CVKDCellectisNASDAQ:CLLSImmunicNASDAQ:IMUXNuvectis PharmaNASDAQ:NVCTView All CompetitorsInstitutional OwnershipPoint72 Asia Singapore Pte. Ltd.Bought 53,027 shares on 8/15/2024Ownership: 0.109%Dimensional Fund Advisors LPSold 217,219 shares on 8/9/2024Ownership: 0.440%Monaco Asset Management SAMSold 81,557 shares on 8/7/2024Ownership: 0.521%View All Institutional Transactions CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $2.64 at the start of the year. Since then, CUE shares have decreased by 77.7% and is now trading at $0.59. View the best growth stocks for 2024 here. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.09. The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $1.12 million. Cue Biopharma had a negative net margin of 566.02% and a negative trailing twelve-month return on equity of 142.93%. Who are Cue Biopharma's major shareholders? Top institutional shareholders of Cue Biopharma include Monaco Asset Management SAM (0.52%), Dimensional Fund Advisors LP (0.44%) and Point72 Asia Singapore Pte. Ltd. (0.11%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Daniel R Passeri, Peter A Kiener and Kerri-Ann Millar. View institutional ownership trends. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV) and Gilead Sciences (GILD). This page (NASDAQ:CUE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free cue Stock Alerts